|
1
|
Hennemann A: Osteoporosis: Prevention,
diagnosis and therapy. Med Monatsschr Pharm. 25:164–167. 2002.(In
German). PubMed/NCBI
|
|
2
|
Burge R, Dawson-Hughes B, Solomon DH, Wong
JB, King A and Tosteson A: Incidence and economic burden of
osteoporosis-related fractures in the United States, 2005–2025. J
Bone Miner Res. 22:465–475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boyle WJ, Simonet WS and Lacey DL:
Osteoclast differentiation and activation. Nature. 423:337–342.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lacey DL, Timms E, Tan HL, Kelley MJ,
Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S,
et al: Osteoprotegerin ligand is a cytokine that regulates
osteoclast differentiation and activation. Cell. 93:165–176. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Karst M, Gorny G, Galvin RJ and Oursler
MJ: Roles of stromal cell RANKL, OPG, and M-CSF expression in
biphasic TGF-beta regulation of osteoclast differentiation. J Cell
Physiol. 200:99–106. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roodman GD: Regulation of osteoclast
differentiation. Ann N Y Acad Sci. 1068:100–109. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yasuda H, Shima N, Nakagawa N, Yamaguchi
K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A,
et al: Osteoclast differentiation factor is a ligand for
osteoprotegerin/osteoclastogenesis-inhibitory factor and is
identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:3597–3602.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takayanagi H, Iizuka H, Juji T, Nakagawa
T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K and
Tanaka S: Involvement of receptor activator of nuclear factor
kappaB ligand/osteoclast differentiation factor in
osteoclastogenesis from synoviocytes in rheumatoid arthritis.
Arthritis Rheum. 43:259–269. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Asagiri M and Takayanagi H: The molecular
understanding of osteoclast differentiation. Bone. 40:251–264.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hemshekhar M, Santhosh Sebastin M, Sunitha
K, Thushara RM, Kemparaju K, Rangappa KS and Girish KS: A dietary
colorant crocin mitigates arthritis and associated secondary
complications by modulating cartilage deteriorating enzymes,
inflammatory mediators and antioxidant status. Biochimie.
94:2723–2733. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li K, Li Y, Ma Z and Zhao J: Crocin exerts
anti-inflammatory and anti-catabolic effects on rat intervertebral
discs by suppressing the activation of JNK. Int J Mol Med.
36:1291–1299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thushara RM, Hemshekhar M, Santhosh MS,
Jnaneshwari S, Nayaka SC, Naveen S, Kemparaju K and Girish KS:
Crocin, a dietary additive protects platelets from oxidative
stress-induced apoptosis and inhibits platelet aggregation. Mol
Cell Biochem. 373:73–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aung HH, Wang CZ, Ni M, Fishbein A,
Mehendale SR, Xie JT, Shoyama CY and Yuan CS: Crocin from Crocus
sativus possesses significant anti-proliferation effects on
human colorectal cancer cells. Exp Oncol. 29:175–180.
2007.PubMed/NCBI
|
|
14
|
Ding Q, Zhong H, Qi Y, Cheng Y, Li W, Yan
S and Wang X: Anti-arthritic effects of crocin in
interleukin-1β-treated articular chondrocytes and cartilage in a
rabbit osteoarthritic model. Inflamm Res. 62:17–25. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao PC, Xiao WX, Yan YB, Zhao X, Liu S,
Feng J, Zhang W, Wang J, Feng YF and Lei W: Preventive effect of
crocin on osteoporosis in an ovariectomized rat model. Evid Based
Complement Alternat Med. 2014:8251812014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suda T, Takahashi N, Udagawa N, Jimi E,
Gillespie MT and Martin TJ: Modulation of osteoclast
differentiation and function by the new members of the tumor
necrosis factor receptor and ligand families. Endocr Rev.
20:345–357. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tanaka S, Nakamura K, Takahasi N and Suda
T: Role of RANKL in physiological and pathological bone resorption
and therapeutics targeting the RANKL-RANK signaling system. Immunol
Rev. 208:30–49. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takayanagi H, Kim S, Koga T, Nishina H,
Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue JI, et
al: Induction and activation of the transcription factor NFATc1
(NFAT2) integrate RANKL signaling in terminal differentiation of
osteoclasts. Deve Cell. 3:889–901. 2002. View Article : Google Scholar
|
|
19
|
Arai A, Mizoguchi T, Harada S, Kobayashi
Y, Nakamichi Y, Yasuda H, Penninger JM, Yamada K, Udagawa N and
Takahashi N: Fos plays an essential role in the upregulation of
RANK expression in osteoclast precursors within the bone
microenvironment. J Cell Sci. 125:2910–2917. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kobayashi N, Kadono Y, Naito A, Matsumoto
K, Yamamoto T, Tanaka S and Inoue J: Segregation of TRAF6-mediated
signaling pathways clarifies its role in osteoclastogenesis. EMBO
J. 20:1271–1280. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grigoriadis AE, Wang ZQ, Cecchini MG,
Hofstetter W, Felix R, Fleisch HA and Wagner EF: c-Fos: A key
regulator of osteoclast-macrophage lineage determination and bone
remodeling. Science. 266:443–448. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huh JE, Lee WI, Kang JW, Nam D, Choi DY,
Park DS, Lee SH and Lee JD: Formononetin attunuates
osteoclastogenesis via suppressing the RANKL-induced activation of
NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1
signaling pathway. J Nat Prod. 77:2423–2431. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ikeda F, Nishimura R, Matsubara T, Tanaka
S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, et
al: Critical roles of c-Jun signaling in regulation of NFAT family
and RANKL-regulated osteoclast differentiation. J Clin Invest.
114:475–484. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miyazaki T, Katagiri H, Kanegae Y,
Takayanagi H, Sawada Y, Yamamoto A, Pando MP, Asano T, Verma IM,
Oda H, et al: Reciprocal role of ERK and NF-kappaB pathways in
survival and activation of osteoclasts. J Cell Biol. 148:333–342.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee ZH and Kim HH: Signal transduction by
receptor activator of nuclear factor kappa B in osteoclasts.
Biochem Biophys Res Commun. 305:211–214. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamashita T, Yao Z, Li F, Zhang Q, Badell
IR, Schwarz EM, Takeshita S, Wagner EF, Noda M, Matsuo K, et al:
NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB
ligand (RANKL) and tumor necrosis factor-induced osteoclast
precursor differentiation by activating c-Fos and NFATc1. J Biol
Chem. 282:18245–18253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Novack DV, Yin L, Hagen-Stapleton A,
Schreiber RD, Goeddel DV, Ross FP and Teitelbaum SL: The IkappaB
function of NF-kappaB2 p100 controls stimulated osteoclastogenesis.
J Exp Med. 198:771–781. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chaisson ML, Branstetter DG, Derry JM,
Armstrong AP, Tometsko ME, Takeda K, Akira S and Dougall WC:
Osteoclast differentiation is impaired in the absence of inhibitor
of kappaB kinase alpha. J Biol Chem. 279:54841–54848. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zou W, Amcheslavsky A, Takeshita S, Drissi
H and Bar-Shavit Z: TNF-alpha expression is transcriptionally
regulated by RANK ligand. J Cell Physiol. 202:371–378. 2005.
View Article : Google Scholar : PubMed/NCBI
|
